Skip to main content
. 2021 Dec 31;18(4):806–815. doi: 10.14245/ns.2142616.308

Table 3.

Comparison of risk factors for the occurrence of PCE in vertebral augmentation group

Factor Vertebral augmentation group (n = 22) Control group 1 (n = 88) p-value
Age (yr) 73.86 ± 11.03 (56–92) 73.39 ± 9.80 (53–90) 0.846
Female sex 19 (86.36) 67 (76.14) 0.394
BMI (kg/m2) 21.43 ± 3.15 (14.95–27.27) 21.78 ± 4.06 (14.69–37.11) 0.641
BMD -3.85 ± 1.13 (-6.6 to -1.3) -3.71 ± 1.33 (-6.2 to -0.2) 0.709
Diagnosis > 0.99
 OVCF 22 (100) 86 (97.27)
 ST 0 (0) 2 (2.27)
Comorbidity
 Diabetes 3 (13.64) 10 (11.36) 0.721
 Hypertension 9 (40.91) 30 (34.09) 0.621
 Chronic pulmonary disease 2 (9.09) 3 (3.41) 0.261
 Coronary heart disease 3 (13.64) 8 (9.09) 0.458
Surgical procedure 0.755
 PVP 18 (81.82) 74 (84.09)
 PKP 4 (18.18) 14 (15.91)
No. of augmented vertebrae 0.041*
 1 or 2 17 (77.27) 82 (93.18)
 3 5 (22.73) 6 (6.82)
Augmented level 0.256
 Thoracic vertebra 21 (60.00) 58 (48.74)
 Lumbar vertebra 14 (40.00) 61 (51.26)
Fracture severity 0.327
 Mild-moderate 24 (65.79) 69 (57.98)
 Severe 11 (34.21) 50 (42.02)
Presence of intravertebral cleft 0.068
 Yes 1 (4.55) 20 (22.73)
 No 21 (95.45) 68 (77.27)
Viscosity of bone cement 0.261
 Low 20 (90.91) 85 (96.59)
 High 2 (9.09) 3 (3.41)
Cement volume per level (mL)
 PVP 4.56 ± 1.81 5.04 ± 1.60 0.376
 PKP 4.10 ± 0.98 5.28 ± 1.69 0.199
Marked leakage in the paravertebral venous plexus 0.000**
 Yes 21 (95.45) 19 (21.59)
 No 1 (4.55) 69 (78.41)
Periods of surgery 0.003**
 2006–2012 16 (72.73) 32 (36.36)
 2013–2019 6 (27.27) 56 (63.64)

Values are presented as number (%) or mean±standard deviation (range).

PCE, pulmonary cement embolism; BMI, body mass index; BMD, bone mineral density; OVCF, osteoporotic vertebral compression fractures; ST, spinal tumors; PVP, percutaneous vertebroplasty; PKP, percutaneous kyphoplasty.

*

p<0.05.

**

p<0.01.